On Friday, Novabay Pharmaceuticals Inc (AMEX: NBY) opened higher 5.12% from the last session, before settling in for the closing price of $0.50. Price fluctuations for NBY have ranged from $0.36 to $10.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 9.88%. Company’s average yearly earnings per share was noted 97.65% at the time writing. With a float of $4.89 million, this company’s outstanding shares have now reached $4.89 million.
Considering the fact that the conglomerate employs 26 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 60.67%, operating margin of -40.03%, and the pretax margin is -98.22%.
Novabay Pharmaceuticals Inc (NBY) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Novabay Pharmaceuticals Inc is 0.01%, while institutional ownership is 2.58%.
Novabay Pharmaceuticals Inc (NBY) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 97.65% per share during the next fiscal year.
Novabay Pharmaceuticals Inc (AMEX: NBY) Trading Performance Indicators
Check out the current performance indicators for Novabay Pharmaceuticals Inc (NBY). In the past quarter, the stock posted a quick ratio of 0.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -35.47, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Novabay Pharmaceuticals Inc (NBY)
Compared to the last year’s volume of 0.9 million, its volume of 0.19 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 24.69%. Additionally, its Average True Range was 0.04.
During the past 100 days, Novabay Pharmaceuticals Inc’s (NBY) raw stochastic average was set at 26.02%, which indicates a significant decrease from 35.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.09% in the past 14 days, which was lower than the 106.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6315, while its 200-day Moving Average is $1.8601. Nevertheless, the first resistance level for the watch stands at $0.5383 in the near term. At $0.5468, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5636. If the price goes on to break the first support level at $0.5130, it is likely to go to the next support level at $0.4962. Should the price break the second support level, the third support level stands at $0.4877.
Novabay Pharmaceuticals Inc (AMEX: NBY) Key Stats
There are currently 4,908K shares outstanding in the company with a market cap of 2.72 million. Presently, the company’s annual sales total 14,730 K according to its annual income of -9,640 K. Last quarter, the company’s sales amounted to 2,440 K and its income totaled -1,210 K.
